| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199802150-00030 |
| P698 | PubMed publication ID | 9484771 |
| P2093 | author name string | Aswad S | |
| Mendez R | |||
| Asai P | |||
| Bogaard T | |||
| Khetan U | |||
| Mendez RG | |||
| Akra I | |||
| Satterthwaite R | |||
| Shidban H | |||
| Sunga V | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypercholesterolemia | Q762713 |
| P304 | page(s) | 446-449 | |
| P577 | publication date | 1998-02-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine | |
| P478 | volume | 65 |
| Q44396416 | A long-term study on hyperlipidemia in stable renal transplant recipients |
| Q43828658 | Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression |
| Q57750639 | Cardiovascular disease in renal transplantation: Management by statins |
| Q84969427 | Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus |
| Q26752168 | Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons |
| Q36062030 | Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens |
| Q35107214 | Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations |
| Q80405145 | Dyslipidemia can reduce the immunosuppressive effects of cyclosporine |
| Q44148770 | Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients |
| Q44713794 | Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients |
| Q44101467 | Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up |
| Q36163801 | Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation |
| Q24200984 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients |
| Q24241098 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients |
| Q50951223 | Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. |
| Q33955184 | Immunosuppression in older renal transplant patients |
| Q44473675 | Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. |
| Q34126617 | Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies |
| Q44412723 | Influence of hypercholesterolemia on patient and graft survival in recipients of kidney transplants |
| Q34421501 | Molecular mechanisms of renal allograft fibrosis |
| Q73314783 | Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation |
| Q64098147 | Neurologic complications of kidney transplantation |
| Q43886135 | Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients |
| Q73304012 | Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience |
| Q34547749 | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients |
| Q51563839 | Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. |
| Q45143164 | Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver |
| Q79781794 | Short-term administration of ACTH improves plasma lipid profile and renal function in kidney transplant patients |
| Q80275700 | Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? |
| Q34566924 | Strategies to reduce toxicities and improve outcomes in renal transplant recipients |
| Q73304043 | Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study |
| Q36669956 | The aetiology and pathogenesis of chronic allograft nephropathy |
| Q34045311 | The metabolic effects of cyclosporin and tacrolimus |
| Q34239244 | Weight gain and cardiovascular risk after organ transplantation |
Search more.